Mark A. Kay, M.D., Ph.D.

Administrative Appointments

• President, American Society of Gene Therapy (2005 - 2006)
• President Elect, American Society of Gene Therapy (2004 - 2005)
• Chair of Organizing Committee, Gordon Conference on Viral Vectors for Gene Therapy (2003 - 2004)
• Vice President, ASGT (2003 - 2004)
• Chief Scientific Advisor, Benitec, LLC (2003 - present)
View All 7administrative appointments of Mark Kay

Honors and Awards

• Researcher of the Year, National Hemophilia Foundation (2000)
• Pediatric Researcher of the Year, E. Mead Johnson Award (2000)
• Elected Member, American Society for Clinical Investigation (1997)
• Arosenius Swedish Honorary Lectureship, - (1997)
• Young Investigator Award, Western Society for Clinical Investigation (1996)

Professional Education

Postdoctoral Advisees

Dan Cao , Shuo Gu , Lan Jin , Hak Kyun Kim , Leszek Lisowski , Jiamiao Lu , Neil Phillips , Biswajoy Roy Chaudhuri , Paul Valdmanis

Graduate & Fellowship Program Affiliations

• Genetics
• Pediatrics

Web Site Links

• Gene Therapy

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Current Research Interests

The goal of the Program in Human Gene Therapy is to develop gene transfer technologies and use them for hepatic gene therapy for the treatment of genetic and acquired diseases. The general approach is to develop new vector systems and delivery methods, test them in the appropriate animal models, uncover the mechanisms involved in vector transduction, and use the most promising approaches in clinical trials. Specifically, we work on a variety of viral and non-viral vector systems. Our major disease models are hemophilia, hepatitis C and B viral infections, and diabetes. The second major focus includes the role that small RNAs play in mammalian gene regulation.

Publications

• Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice. Beer S, Bellovin DI, Lee JS, Komatsubara K, Wang LS, Koh H, Börner K, Storm TA, Davis CR, Kay MA, Felsher DW, Grimm D. Mol Ther. 2010; 18 (1): 161-70
• Gene Transfer to Mouse Heart and Skeletal Muscles Using a Minicircle Expressing Human Vascular Endothelial Growth Factor. Stenler S, Andersson A, Simonson OE, Lundin KE, Chen ZY, Kay MA, Smith CI, Sylvén C, Blomberg P. J Cardiovasc Pharmacol. 2009
• Biological basis for restriction of microRNA targets to the 3' untranslated region in mammalian mRNAs. Gu S, Jin L, Zhang F, Sarnow P, Kay MA. Nat Struct Mol Biol. 2009; 16 (2): 144-50
• Novel minicircle vector for gene therapy in murine myocardial infarction. Huang M, Chen Z, Hu S, Jia F, Li Z, Hoyt G, Robbins RC, Kay MA, Wu JC. Circulation. 2009; 120 (11 Suppl): S230-7
• Combined proteomic-RNAi screen for host factors involved in human hepatitis delta virus replication. Cao D, Haussecker D, Huang Y, Kay MA. RNA. 2009; 15 (11): 1971-9